Trial Profile
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Telaglenastat (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma
- Focus Adverse reactions
- 07 Dec 2023 Planned End Date changed from 5 Dec 2023 to 5 Dec 2024.
- 07 Dec 2023 Planned primary completion date changed from 5 Dec 2023 to 5 Dec 2024.
- 07 Dec 2022 Planned End Date changed from 5 Dec 2022 to 5 Dec 2023.